Pharma's Almanac TV
PA TV
Dashboard
Your Name
Your Email
Manage Account
Sign Out
Sign In
Register
Topics
Products
ADC
API - Small Molecule
Biologics
Biopharmaceuticals
Biosimilars
Cell and Gene Therapy
DNA
Drug Product
Drug Substance
Equipment
Generics
Immunotherapy
Injectables
Monoclonal Antibody
Novel Therapeutics
Oral Solid Dosage
Orphan Drugs
Parenterals
Stem Cells
Vaccine
Services
Big Data
Bioprocessing
Clinical Trials
Continuous Manufacturing
Diagnostics
Drug Delivery
Drug Development
Drug Discovery
Facility
Formulation
Innovation
Oncology
Patient Adherence
Patient Centric
Preclinical
Process Development
Quality
Regulatory
Research
Serialization
Segment
Biomanufacturing
Biotechnology
CDMO
Consulting
CRO
Engineering
Equipment
Excipients
Healthcare
Intermediates
Logistics
Manufacturing
Packaging
Supply Chain
Business
Agreement
Appointment
Business
Capacity Expansion
Collaboration
Growth
Investment
Licensing
M&A
Market Expansion
Market Intelligence
Market Prediction
New Facility
Strategic Partnership
Analytics
Research
CDMO
CRO
Excipients
Pharmaceutical Equipment
Pharmaceutical Intermediates
Supply Chain Logistics
Magazine
Current Issue
Archive
Community
Company A to Z
Content Filter
More+
Staffing
Media Kit
By The Numbers
Clinical Trials
435 Articles Available
1
19
Can't find what you're looking for? Try our
advanced search
.
Biohaven to Advance Vazegepant Into Phase 3 for Acute Migraine Treatment
PR-M03-20-NI-036
Vaccitech and Oxford University Announce Promising Phase 2a Data on Prostate Cancer Immunotherapy
PR-M03-20-NI-036
COVID-19
Roche Initiates Phase III Clinical Trial of Actemra/RoActemra in Patients with Severe COVID-19 Pneumonia
PR-M03-20-NI-030
Clinical Trials
FDA Urges Remote Clinical Trials
PR-M03-20-NI-029
Coronavirus
Gilead Sciences Initiates Two Phase 3 Studies of Investigational Antiviral Remdesivir for the Treatment of COVID-19
PR-M02-20-NI-037
Clinical Trials
Regulus Therapeutics Reinitiates Multiple Ascending Dose Study of RGLS4326 for the Treatment of ADPKD
PR-M02-20-NI-023
Coronavirus
Gilead Sciences Begins Trial on Treatment for Coronavirus (2019-nCoV)
PR-M02-20-NI-003
Drug Development
Insmed Announces Positive Top-Line Results from Phase 2 WILLOW Study of INS1007 in Patients with Non-Cystic Fibrosis Bronchiectasis
PR-M01-20-NI-048
Clinical Trials
Roche’s Risdiplam Meets Primary Endpoint in Pivotal FIREFISH Trial
PR-M01-20-NI-036
Cancer Treatment
NantKwest and ImmunityBio Announce Complete Response in Metastatic Pancreatic Cancer Patient
PR-M01-20-NI-020
Clinical Trial
Agenus Commences Combination Trial of its Next-Gen CTLA-4 with its PD-1 Antibody
PR-M12-19-NI-033
Clinical Trials
VistaGen and Baylor College of Medicine Announce Successful Results of Study Treating Suicidal Ideation in Veterans
PR-M12-19-NI-031
Clinical Trial Logistics
Integrated Ancillary Sourcing Services for Clinical Trials
PAO-12-19-CL-001
Clinical Results
Biohaven Achieves Positive Topline Results for Intranasal Migraine Treatment
PR-M12-19-NI-025
Immunotherapy
NantKwest and ImmunityBio Present Results of Landmark Trial of First-in-Human Combination Immunotherapy in Triple Negative Breast Cancer
PR-M12-19-NI-022
Multiple Myeloma
Janssen Reports Positive Results for DARZALEX® in Multiple Myeloma
PAO-M12-19-NI-006
Clinical Trial Logistics
Expediting Clinical Trials with a Global Transportation Footprint and Clinical Packaging
PAP-Q4-19-CL-034
Investment in Innovation
Should You Choose a Commercial HPAPI Manufacturer for Your Clinical Program?
PAO-11-2019-CL-001
Translational Pharmaceutics
Measuring the Time and Cost Benefits of Integrated Product Development
PAP-Q4-19-CL-017
Clinical Results
ACADIA Pharmaceuticals Presents Positive Top-line Results from Dementia-Related Psychosis Trial
PR-M12-19-NI-012
Capacity Expansion
PCI Unveils Expanded Clinical Center in Midwest
PR-M12-19-NI-006
Cell and Gene Therapy
CRISPR Therapeutics and Vertex Announce Positive Safety and Efficacy Data From First Two Patients Treated With Investigational CRISPR/Cas9 Gene-Editing Therapy CTX001® for Severe Hemoglobinopathies
PR-M11-19-NI-023
Clinical Results
VistaGen Reports Topline Phase 2 Results for AV-101 as an Adjunctive Treatment of Major Depressive Disorder
PR-M11-19-NI-019
Drug Development
WuXi Biologics Congratulates Tychan on the World’s First Yellow Fever Antibody Tested Safe and Efficacious in Human Volunteers
PR-M11-19-NI-018
1
19
»
